BMG Seminar: Gen-Sheng Feng, PhD, UCSD
When:
Thursday, September 22, 2022
10:00 AM - 11:00 AM CT
Where: Simpson Querrey Biomedical Research Center, Simpson Querrey Auditorium, 303 E. Superior Street, Chicago, IL 60611 map it
Audience: Faculty/Staff - Student - Post Docs/Docs - Graduate Students
Contact:
Linda Mekhitarian Jackson
(312) 503-5229
Group: Biochemistry & Molecular Genetics Seminar Series
Category: Lectures & Meetings
Description:
The Department of Biochemistry and Molecular Genetics presents:
Gen-Sheng Feng, PhD
Professor, Departments of Pathology and Molecular Biology
University of California San Diego
Presentation: ”Shp2 and Cell Signaling in Health and Disease, 30 years”
Abstract:
Dr. Gen-Sheng Feng is Professor of Pathology and Molecular Biology at the University of California, San Diego (UCSD).
Dr. Feng obtained his Ph.D. degree in Microbiology from Indiana University Bloomington in 1990 and received postdoctoral training at the Hospital for Sick Children and Mt Sinai Hospital, Toronto, Canada. Dr. Feng was Assistant and Associate Professor in Biochemistry and Molecular Biology at Indiana University School of Medicine, from 1994 to 1999. He moved his lab to the Burnham Institute, La Jolla, in 2000, and joined UCSD in 2009.
Dr. Feng has made seminal contributions to the understanding of cross-talks and regulation of signaling pathways in various cell types in health and diseases. This work was initiated by discovery of an SH2-containing tyrosine phosphatase Shp2 (Syp) in his postdoc studies (Feng et al., Science, 1993). His research has led to establishment of a dogma that a PTP promotes signaling from RTKs to the Ras/Erk pathway. His group was the first to identify a positive role of Shp2 in control of embryonic, hematopoietic and neural stem cell differentiation. He has contributed to deciphering Shp2 as the first oncogenic tyrosine phosphatase in cancer.
The current focus of his lab is on elucidating the paradoxical anti-oncogenic effects of classical oncoproteins in hepato-carcinogenesis, which his and other labs identified recently. This line of research provides fresh views on liver cancer initiation and progression, and identifies novel targets for early detection and therapy of the malignant disease. By elucidating multi-faceted roles of the immune ecosystem, Dr. Feng is developing new thoughts and strategies for design of combinatorial liver cancer immunotherapy through coordinated activation of innate and adaptive immune cells.
Host: Dr. Shannon Lauberth, Associate Professor, Biochemistry and Molecular Genetics